• Melanoma
    Categories: ,

    Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)

    8 Jan 2018

  • Melanoma
    Categories: ,

    EORTC study published in NEJM shows prolonged survival in stage III melanoma

    8 Oct 2016

  • alexander-eggermont
    Categories: ,

    FDA Approves Adjuvant Yervoy in Melanoma based on results of EORTC trial 18071

    13 Nov 2015

  • alexander-eggermont
    Categories: ,

    Will adjuvant pembrolizumab improve recurrence-free survival for patients with high-risk Stage III melanoma?

    14 Sep 2015

  • Alexander van Akkooi
    Categories: ,

    EORTC opens prospective registry for patients with Melanoma

    12 Jun 2015

  • alexander-eggermont
    Categories: ,

    Adjuvant Ipilimumab significantly effects recurrence-free survival in patients after resection of high risk lymph node positive melanoma

    20 Apr 2015

  • chicago
    Categories: , ,

    Pr Alexander Eggermont presented the initial efficacy and safety results from EORTC trial 18071 at ASCO 2014 in Chicago

    11 Jun 2014

  • vaccin
    Categories: , ,

    Vaccination with GM2-KLH-QS21 does not improve outcome stage II melanomas patients in EORTC study

    13 Sep 2013